## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed nursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Title of Security (Instr. 3) 2. Transaction Date		2. Transaction	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an	d 5)	. Amount of securities seneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
		Table I	lon Dorivative	o Socuritios A	cauirod D	ispased of ar Panafi	oially	Owned				
(City)	(State)	(Zip)										
SAN FRANCISCO	CA	94158					X	•	one Reporting Pe lore than One R			
(Street)			4.1	If Amendment, Date	of Original Fi	led (Month/Day/Year)	6. Indiv	vidual or Joint/Gro	up Filing (Check	Applicable		
409 ILLINOIS	ST.											
C/O FIBROGE	N, INC.			/20/2018	isaction (WOII	undayi icai j		Chief Ex	ecutive Officer			
(Last) (First) (Middle)				Date of Earliest Trar	nsaction (Mon	th/Day/Vear)	X	Officer (give title below)	e Othe belo	er (specify ow)		
Neff Thomas	<u>s B</u>			<u>IBROGEN IN</u>	<u>C</u> [ FGEN	J	X	Director	10%	ó Owner		
1. Name and Addre	ss of Reporting	Person*		Issuer Name <b>and</b> Ti			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
						Company Act of 1940						

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities of Disposed Of			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(111511.4)
Common Stock	06/20/2018		M		10,320	A	\$3.6	2,856,353	D	
Common Stock	06/20/2018		S		7,701 <sup>(1)</sup>	D	\$63.31(2)	2,848,652	D	
Common Stock	06/20/2018		S		11,199(1)	D	\$63.79(3)	2,837,453	D	
Common Stock	06/20/2018		S		798(1)	D	\$63.55(4)	108,684	I	By Family Partnership
Common Stock	06/20/2018		S		120(1)	D	\$63.97(5)	108,564	I	By Family Partnership
Common Stock	06/21/2018		M		10,320	A	\$3.6	2,847,773	D	
Common Stock	06/21/2018		S		15,172 <sup>(1)</sup>	D	\$63.54(6)	2,832,601	D	
Common Stock	06/21/2018		S		3,728(1)	D	\$64.08(7)	2,828,873	D	
Common Stock	06/21/2018		S		918(1)	D	\$63.6(8)	107,646	I	By Family Partnership
Common Stock								19,500	I	By Spouse
Common Stock								60,946	I	See footnote <sup>(9)</sup>

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(e.g., pare, carret marraine, opinione, control and co														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$3.6	06/20/2018		M			10,320	(10)	03/11/2019	Common Stock	10,320	\$0.00	340,541	D	
Stock Option (Right to Buy)	\$3.6	06/21/2018		М			10,320	(10)	03/11/2019	Common Stock	10,320	\$0.00	330,221	D	

### **Explanation of Responses:**

- 1. Shares sold pursuant to a 10b5-1 plan.
- 2. The shares were sold at prices ranging from \$62.55 to \$63.525. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 3. The shares were sold at prices ranging from \$63.55 to \$64.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 4. The shares were sold at prices ranging from \$62.90 to \$63.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of

shares sold at each separate price.

- 5. The shares were sold at prices ranging from \$63.95 to \$63.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 6. The shares were sold at prices ranging from \$63.10 to \$63.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 7. The shares were sold at prices ranging from \$64.00 to \$64.225. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

  8. The shares were sold at prices ranging from \$63.20 to \$63.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of
- shares sold at each separate price.

  9. The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth
- 9. The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.

10. Fully vested.

#### Remarks:

/s/ Dorothy Pacini, Attorney-infact 06/22/2018

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.